ORIGINAL ARTICLE

The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics

Vivek Kumar 1,*, Ashok Kumar Yadav 2,*, Jasmine Sethi 1, Arpita Ghosh 3, Manisha Sahay 4, Narayan Prasad 5, Santosh Varughese 6, Sreejith Parameswaran 7, Natarajan Gopalakrishnan 8, Prabhjot Kaur 1, Gopesh K. Modi 9, Kajal Kamboj 1, Monica Kundu 3, Vivek Sood 1, Neeraj Inamdar 1, Ajay Jaryal 10, Sanjay Vikrant 10, Saurabh Nayak 1, Shivendra Singh 11, Sishir Gang 12, Seema Baid-Agrawal 13 and Vivekanand Jha 3,14,15,

1Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 3George Institute for Global Health India, New Delhi, India, 4Department of Nephrology, Osmania Medical College, Osmania General Hospital, Hyderabad, India, 5Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India, 6Department of Nephrology, Christian Medical College, Vellore, India, 7Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India, 8Department of Nephrology, Rajiv Gandhi Government General Hospital, Chennai, India, 9Samarpan Kidney Institute and Research Center, Bhopal, India, 10Department of Nephrology, Indira Gandhi Medical College, Shimla, India, 11Department of Nephrology, Institute of Medical Science, Banaras Hindu University, Varanasi, India, 12Department of Nephrology, Muljiibhai Patel Urological Hospital, Nadiad, India, 13Department of Nephrology and Transplant Center, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden, 14School of Public Health, Imperial College, London, UK and 15Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India

*These authors contributed equally to this work.
Correspondence to: Vivekanand Jha; E-mail: vjha@georgeinstitute.org.in

ABSTRACT

Background. Chronic kidney disease (CKD) is an important cause of morbidity and mortality worldwide. There is a lack of information on epidemiology and progression of CKD in low–middle income countries. The Indian Chronic Kidney Disease (ICKD) study aims to identify factors that associate with CKD progression, and development of kidney failure and cardiovascular disease (CVD) in Indian patients with CKD.
Methods. ICKD study is prospective, multicentric cohort study enrolling patients with estimated glomerular filtration rate (eGFR) 15–60 mL/min/1.73 m², or >60 mL/min/1.73 m² with proteinuria. Clinical details and biological samples are collected at annual visits. We analysed the baseline characteristics including socio-demographic details, risk factors, disease characteristics and laboratory measurements. In addition, we compared characteristics between urban and rural participants.

Results. A total of 4056 patients have been enrolled up to 31 March 2020. The mean ± SD age was 50.3 ± 11.8 years, 67.2% were males, two-thirds of patients lived in rural areas and the median eGFR was 40 mL/min/1.73 m². About 87% were hypertensive, 37% had diabetes, 22% had CVD, 6.7% had past history of acute kidney injury and 23% reported prior use of alternative drugs. Diabetic kidney disease, chronic interstitial nephritis (CIN) and CKD-cause unknown (CKDu) were the leading causes. Rural participants had more occupational exposure and tobacco use but lower educational status and income. CIN and unknown categories were leading causes in rural participants.

Conclusions. The ICKD study is the only large cohort study of patients with mild-to-moderate CKD in a lower middle income country. Baseline characteristics of study population reveal differences as compared with other cohorts from high-income countries.

Keywords: alternative drugs, chronic kidney disease, chronic interstitial nephritis, cohort study, rural health, socioeconomic factors

INTRODUCTION

Global Burden of Disease collaboration identifies chronic kidney disease (CKD) as a major contributor to global morbidity and mortality [1]. Between 1990 and 2017, the global all-age prevalence and mortality from CKD increased by 29.3 and 41.5%, respectively [1]. In India, there was a 38% increase in the proportion of deaths attributable to kidney failure between 2001–03 and 2010–13 [2]. CKD is also an important cardiovascular disease (CVD) risk factor, the leading cause of premature deaths and disability-adjusted life years. Opportunities for secondary and tertiary prevention in CKD are often missed in developing countries like India [3]. Patients seek medical attention when they are symptomatic, usually late in the course of disease. CKD only comes to light in earlier stages when kidney function evaluation is done for either other health conditions or, less commonly, for routine screening [4]. When coupled with the fact that the major burden of CKD is concentrated in regions with lower socio-demographic indices [1], it becomes clear that risk factor identification and mitigation strategies in CKD will be globally successful only when the unique challenges of these regions are addressed.

The development and outcomes of CKD are impacted by local factors like aetiological spectrum influenced by local risk factors, genetic differences, socio-demographic variables and access to healthcare resources. Cohort studies in patients with CKD have been established in the USA, Germany, Canada, France, Spain, Japan, Republic of South Korea and China [5–11]. These have allowed compilation of a wealth of scientific data that have informed local research and clinical care priorities, as well as international cooperation and comparisons such as the International Network of CKD cohort studies of the International Society of Nephrology [12–14].

The Indian CKD (ICKD) study [15] is a publicly funded cohort study that aims to explore risk factors for progression of CKD, development of CVD and differences in outcomes based on gender, socio-demographic profile and regions, and quality of life and cost of care in a CKD population representing all parts of India. In the present manuscript, we report baseline characteristics of participants enrolled in the ICKD study.

MATERIALS AND METHODS

Study design and setting

The ICKD study is a multicentric, prospective cohort study of patients with mild-to-moderate CKD in India. Participants are recruited in large nephrology services across 11 centres distributed throughout the country (Supplementary Appendix S1: map showing location of centres across India). The study procedures were developed, harmonized and adapted to ensure comparability of data with other International cohorts of patients with CKD. Expert consultations were held to decide on questions about possible risk factors in CKD perceived to be relevant in local context. The study has a distributed biobank, with a local biobank at each centre and the central one at Post-graduate Institute of Medical Education and Research, Chandigarh. The detailed design and methods of the study have been published [15]. The study has been approved by Ethics Committees at each participating centre.

Study population

Clinically stable adult patients aged between 18 and 70 years with estimated glomerular filtration rate (eGFR) by creatinine-based CKD Epidemiology Collaboration (CKD-EPI) equation of either 15–60 mL/min/1.73 m², or >60 mL/min/1.73 m² and proteinuria (urine protein to creatinine ratio >500 mg/g or albumin to creatinine ratio >300 mg/g or equivalent) were approached for consent and recruitment. Organ transplant recipients, pregnant females or those with malignancy, life expectancy <1 year or on current immunosuppressive drug therapy were excluded.

Study measurements and conduct

Details of socio-demographic status, family history, history of CKD risk factors, CVD, acute kidney injury (AKI), comorbidities, occupation, addictions and treatment details including the use of alternative drugs were recorded (Supplementary Appendix S2: baseline questionnaire, Supplementary data, Table S1: definitions/interpretations used for the present analysis in context of data captured in baseline questionnaire). The responses were
RESULTS

A total of 4056 participants were enrolled in the cohort between 1 April 2016 and 31 March 2020 in Phase I of the study. The socio-demographic characteristics of the participants are shown in Table 1. The average age at recruitment is 50.3 ± 11.8 years, with 67.2% of the population being males. Two-thirds of the population lived in rural areas, and 73% had received some formal education. About 35% were vegetarians. Among those classified as non-vegetarians, the frequency of meat consumption (includes meat, fish and fowl) was 4.5 times every month. About 43% of the study population was physically active, and 7.5% and 18.6% participants were current alcohol and tobacco users, respectively. The median (25–75th percentiles) annual expenditure on medical care was US$286 (84–571), which represented ~17% of the median total annual household income of US$1680 (1008–4200). Only 32.1% of the participants had any medical insurance. About 83% incurred out-of-pocket expenditure for CKD care. Only 10.6% of the participants admitted to missing scheduled hospital visits or drugs on account of financial constraints.

Clinical characteristics

The most common cause of CKD was DKD (24.9%), followed by CIN and unknown in 23.2 and 19.5%, respectively (Table 2). The mean duration of kidney disease at the time of recruitment into the study was 38.3 ± 53.0 months (Table 1). Family history of hypertension, diabetes mellitus and stroke were recorded in 43.1%, 37.4% and 14%, respectively. In terms of risk factors, 87% were hypertensive and 37.5% had diabetes, whereas 22.9% reported history of using alternative drugs (local or indigenous forms of medicine). History of nephrolithiasis and recurrent urinary tract infections (UTIs) were present in 11.8 and 11%, respectively. About 9% of the participants reported a family history of kidney disease. Prior history suggestive of AKI was recorded in 6.7% of study population. About 33% of females reported adverse outcome events during pregnancy. Only 21.8% of participants had prior CVD. The median (25–75th percentiles) body mass index (BMI) and waist/hip ratio in study population were 24.4 (21.6–27.4) kg/m² and 1.05 (1.02–1.09), respectively (Table 1).

Laboratory characteristics

The median (25th–75th percentiles) serum creatinine and eGFR were 1.7 (1.5–2.0) mg/dL and 40.5 (33.7–50.8) mL/min/1.73 m², respectively (Table 3). Albuminuria (trace or more) by urine dipstick examination was present in 41.4% of the participants, with the calculated uACR being >300 mg/g in 25.5%. Median (25–75th percentiles) haemoglobin (Hb), serum albumin, calcium, inorganic phosphorus and uric acid were 11.8 (10.5–13.2) g/dL, 4.0 (3.5–4.4) g/dL, 9.0 (8.5–9.4) mg/dL, 4.0 (3.3–4.5) mg/dL and 6.4 (5.2–7.6) mg/dL, respectively. About 6.3% and 6.5% of the participants had positive hepatitis B surface antigen and antibodies against hepatitis C virus, respectively (Table 3).

Rural–urban comparisons

The socio-demographic, clinical and biochemical characteristics of the rural and urban participants are described in Tables 4 and 5. Age was similar between the groups. Compared with urban participants, those from rural areas had more occupational exposure (54.6% versus 41.5%, P < 0.001), higher tobacco use (20.6% versus 15.1%, P < 0.001), lower level of education (66.8% versus
Table 1. Socio-demographic characteristics of participants in the study cohort

| Characteristic                  | Females (n = 1331) | Males (n = 2725) | Total (n = 4056) | Missing, n (%) | P-values |
|---------------------------------|--------------------|------------------|------------------|----------------|----------|
| Age, years                      | 49.0 ± 11.6        | 50.9 ± 11.9      | 50.3 ± 11.8      | 0 (0)          | <0.001   |
| Duration of kidney disease, months | 40.8 ± 55.6       | 37.1 ± 51.6      | 38.3 ± 53.0      | 32 (0.8)       | 0.039    |
| BMI, kg/m²                       | 25.3 (21.2–29.0)   | 24.0 (21.5–26.7) | 24.4 (21.6–27.4) | 103 (2.5)      | <0.001   |
| Waist/hip ratio                 | 1.06 (1.02–1.21)   | 1.05 (1.01–1.08) | 1.05 (1.02–1.09) | 964 (23.8)     | <0.001   |
| Place of residence              |                    |                  |                  |                |          |
| Rural                           | 845 (65.2)         | 1781 (66.5)      | 2626 (66.0)      | 80 (2.0)       | 0.407    |
| Urban                           | 452 (34.8)         | 898 (33.5)       | 1350 (34.0)      |                |          |
| Education                       |                    |                  |                  |                |          |
| Illiterate                      | 524 (39.6)         | 564 (20.8)       | 1088 (26.9)      | 18 (0.4)       | <0.001   |
| School level education          | 582 (44.0)         | 1330 (49.0)      | 1912 (47.4)      |                |          |
| Went to college                 | 216 (16.4)         | 822 (30.2)       | 1038 (25.7)      |                |          |
| Occupational exposure²          | 629 (47.6)         | 1406 (51.8)      | 2035 (50.4)      | 18 (0.4)       | 0.013    |
| Sand/dust                       | 228 (17.3)         | 618 (22.8)       | 846 (21.0)       |                |          |
| Cement                          | 7 (0.5)            | 81 (2.98)        | 88 (2.2)         |                |          |
| Saw dust                        | 34 (2.6)           | 112 (4.1)        | 146 (3.6)        |                |          |
| Working barefoot in field       | 58 (4.4)           | 204 (7.5)        | 262 (6.5)        |                |          |
| Pesticide spray                 | 41 (3.1)           | 186 (6.9)        | 227 (5.6)        |                |          |
| Others                          | 356 (26.6)         | 593 (22.2)       | 949 (24.6)       |                |          |
| Current tobacco user            | 87 (6.6)           | 660 (24.5)       | 747 (18.6)       | 43 (1.1)       | <0.001   |
| Current alcohol user            | 1 (0.1)            | 300 (11.1)       | 301 (7.5)        | 43 (1.1)       | <0.001   |
| Physically active               | 479 (36.4)         | 1239 (45.9)      | 1718 (42.8)      | 43 (1.1)       | <0.001   |
| Non-vegetarian diet             | 830 (63.5)         | 1771 (66.2)      | 2601 (66.8)      | 75 (1.9)       | 0.090    |
| Access to piped water supply    | 693 (52.4)         | 1282 (47.2)      | 1975 (48.9)      | 18 (0.4)       | 0.003    |
| Annual household income (USD)   | 1680 (840–4200)    | 1680 (1008–4200) | 1680 (1008–4200) | 41 (1.9)       | 0.176    |
| Annual household medical        | 269 (84–571)       | 302 (84–571)     | 286 (84–571)     | 0 (0.0)        | 0.742    |
| expenditure (USD)               |                    |                  |                  |                |          |
| Medical insurance               | 432 (33.2)         | 844 (31.5)       | 1276 (32.1)      | 77 (1.9)       | 0.284    |
| Incurred out of pocket medical expenditure | 1115 (84.3) | 2237 (82.4) | 3352 (83.0) | 18 (0.4) | 0.034 |
| Missed hospital visit/drugs due to financial constraints | 135 (10.2) | 293 (10.8) | 428 (10.6) | 18 (0.4) | 0.577 |

Data are presented as mean ± SD, median (25–75th percentile) or n (%).

²Occupational exposure—has multiple responses.

Table 2. Clinical characteristics and diagnosis of CKD in the study cohort

| Parameter                             | Females (n = 1331) | Males (n = 2725) | Total (n = 4056) | Missing, n (%) | P-values |
|---------------------------------------|--------------------|------------------|------------------|----------------|----------|
| Clinical characteristics              |                    |                  |                  |                |          |
| Hypertension                          | 1130 (86.1)        | 2357 (87.5)      | 3487 (87.0)      | 49 (1.2)       | 0.240    |
| Diabetes                              | 473 (36.6)         | 1012 (37.9)      | 1485 (37.5)      | 96 (2.4)       | 0.456    |
| CVD                                   | 255 (19.4)         | 621 (23.0)       | 876 (21.8)       | 33 (0.8)       | 0.009    |
| Renal stone disease                   | 139 (10.5)         | 335 (12.4)       | 474 (11.3)       | 27 (0.7)       | 0.092    |
| Recurrent UTI                         | 144 (10.9)         | 298 (11.0)       | 442 (10.9)       | 27 (0.7)       | 0.940    |
| Alternative drug use                  | 284 (21.5)         | 639 (23.5)       | 923 (22.9)       | 16 (0.4)       | 0.150    |
| Ayurvedic                             | 108 (38.0)         | 256 (40.0)       | 364 (39.5)       | —              | —        |
| Homoeopathic                          | 51 (18.0)          | 158 (24.7)       | 209 (22.6)       | —              | —        |
| Siddha                                | 21 (7.4)           | 30 (4.7)         | 51 (5.5)         | —              | —        |
| Unani                                 | 8 (2.8)            | 5 (0.8)          | 13 (1.4)         | —              | —        |
| Others                                | 96 (33.8)          | 190 (29.8)       | 286 (31.0)       | —              | —        |
| NSAID use                             | 251 (19.1)         | 375 (13.9)       | 626 (15.6)       | 43 (1.1)       | <0.001   |
| History of AKI                        | 91 (6.9)           | 177 (6.6)        | 268 (6.7)        | 43 (1.1)       | 0.668    |
| Required dialysis for AKI             | 88 (6.7)           | 143 (5.3)        | 231 (5.8)        | 43 (1.1)       | 0.076    |
| Underwent renal biopsy                | 228 (17.3)         | 458 (17.0)       | 686 (17.1)       | 43 (1.1)       | 0.774    |
| Family history                        |                    |                  |                  |                |          |

(continued)
85.4%, \( P < 0.001 \) and non-vegetarian dietary status (68.2% versus 59.9%, \( P < 0.001 \)). Compared with the urban participants, the median annual household income was almost half in the rural group [US dollars (USD) 1680 versus 3024, \( P < 0.001 \)]. Fewer patients in the rural regions had medical insurance (27.8% versus 39.8%, \( P < 0.001 \)). History of use of alternative drugs (26.4% versus 21.4%, \( P < 0.001 \)), BMI and family history of hypertension or diabetes were more in the urban group. uACR was lower among rural participants (25.5 versus 41.0 mg/g, \( P = 0.003 \)).

### Table 2. (continued)

| Parameter            | Females (n = 1331) | Males (n = 2725) | Total (n = 4056) | Missing, n (%) | P-values |
|----------------------|--------------------|-----------------|-----------------|----------------|----------|
| Hypertension         | 525 (43.0)         | 1088 (43.1)     | 1613 (43.1)     | 309 (7.6)      | 0.141    |
| Diabetes             | 475 (39.4)         | 915 (36.4)      | 1390 (37.4)     | 337 (8.3)      | 0.200    |
| Kidney disease       | 127 (9.6)          | 231 (8.5)       | 358 (8.9)       | 30 (0.7)       | 0.502    |
| Kidney stones        | 22 (17.3)          | 41 (17.7)       | 63 (17.6)       | –              | –        |
| Dialysis             | 35 (27.6)          | 71 (30.7)       | 106 (29.6)      | –              | –        |
| Kidney transplant    | 5 (3.9)            | 13 (5.6)        | 18 (5.0)        | –              | –        |

### Cause of CKD

- **DKD**
- **CIN**
- **Unknown**
- **CGN**
- **Hypertensive nephrosclerosis**
- **PKD**
- **Others**

### Table 3. Physical and biochemical characteristics of participants in the study cohort

| Characteristic                  | Females (n = 1331) | Males (n = 2725) | Total (n = 4056) | Missing, n (%) | P-values |
|---------------------------------|--------------------|-----------------|-----------------|----------------|----------|
| SBP, mmHg                        | 130 (120–141)      | 130 (120–145)   | 130 (120–144)   | 101 (2.5)      | 0.006    |
| DBP, mmHg                        | 80 (76–90)         | 80 (78–90)      | 80 (78–90)      | 133 (3.3)      | 0.010    |
| eGFR, ml/min/1.73 m²             | 36.3 (30.7–45.3)   | 42.9 (35.7–52.3)| 40.5 (33.7–50.8)| 0              | <0.001   |
| Hb, mg/dL                       | 11.0 (10.0–12.0)   | 12.4 (11–13.7)  | 11.8 (10.5–13.2)| 143 (3.5)      | <0.001   |
| Anaemia*                        | 932 (73.2)         | 1607 (60.9)     | 2539 (64.9)     | 143 (3.5)      | <0.001   |
| Mild                            | 329 (25.8)         | 976 (37.0)      | 1305 (33.4)     | –              | –        |
| Moderate                        | 579 (45.5)         | 597 (22.6)      | 1176 (30.1)     | –              | –        |
| Severe                          | 24 (1.9)           | 94 (3.1)        | 118 (2.9)       | 58 (1.5)       | 0.788    |
| Serum creatinine, mg/dL         | 4.5 (3.5–5.6)      | 4.5 (3.4–5.6)   | 4.5 (3.4–5.6)   | 571 (14.1)     | 0.788    |
| Serum calcium, mg/dL            | 1.6 (1.4–1.9)      | 1.8 (1.5–2.1)   | 1.7 (1.5–2.0)   | 0              | <0.001   |
| Serum inorganic phosphorus, mg/dL| 8.9 (8.4–9.4)    | 9.0 (8.6–9.5)   | 9.0 (8.5–9.4)   | 290 (7.2)      | 0.0001   |
| Serum albumin, g/dL             | 4.1 (3.6–4.6)      | 3.9 (3.2–4.4)   | 4.0 (3.3–4.5)   | 340 (8.4)      | <0.001   |
| Serum uric acid, mg/dL          | 3.9 (3.4–4.2)      | 4.0 (3.5–4.4)   | 4.0 (3.5–4.4)   | 225 (5.6)      | <0.001   |
| Total cholesterol, mg/dL        | 173 (140–203)      | 162 (130–198)   | 166 (133–200)   | 1538 (37.9)    | <0.001   |
| Triglycerides, mg/dL            | 140 (112–180)      | 136 (108–175)   | 138 (110–177)   | 1647 (40.6)    | 0.202    |
| HbsAg                           | –                  | 170 (6.2)       | 255 (6.3)       | 6 (0.2)        | –        |
| Positive                        | 750 (56.5)         | 1614 (59.3)     | 2364 (58.4)     | –              | –        |
| Negative                        | 493 (37.1)         | 938 (34.3)      | 1431 (35.3)     | –              | –        |
| Anti-HCV                        | –                  | 167 (6.1)       | 264 (6.5)       | 6 (0.2)        | –        |
| Positive                        | 97 (7.3)           | 167 (6.1)       | 264 (6.5)       | 6 (0.2)        | –        |
| Negative                        | 707 (53.2)         | 1530 (56.2)     | 2237 (55.2)     | –              | 0.132    |
| Not available                   | 524 (39.5)         | 1025 (37.7)     | 1549 (38.3)     | –              | –        |
| uACR, mg/g                      | 45 (12–35.7)       | 26 (11–280)     | 29 (11–304)     | 272 (6.7)      | <0.001   |
| <30                             | 573 (65.9)         | 1330 (68.4)     | 1903 (67.6)     | –              | –        |
| 30–299                          | 296 (34.1)         | 616 (31.7)      | 912 (32.4)      | –              | –        |
| 300–1000                        | 234 (18.9)         | 349 (13.7)      | 583 (15.4)      | –              | –        |
| >1000                           | 133 (10.8)         | 251 (9.8)       | 384 (10.1)      | –              | –        |

Data are presented as median (25–75th percentile) or n (%).

*Anaemia was classified as per World Health Organization criteria: mild anaemia, Hb 11.0–11.9 mg/dL for females and 11–12.9 mg/dL for males; moderate anaemia, Hb 8.0–10.9 mg/dL for females and males; and severe anaemia, Hb < 8 mg/dL for females and males.*

SBP, systolic BP; DBP, diastolic BP; HbA1c, glycosylated Hb; HbsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
rural group, whereas DKD and CGN were more in the urban group.

**DISCUSSION**

This is the first paper to provide a comprehensive description of a nationwide cohort of patients with mild-to-moderate CKD from a developing country like India. The enrolled cohort is representative of the general Indian population in terms of age, sex ratio, representation of rural population, income and education levels, and other socio-economic characteristics according to the National Census [17].

The ICKD cohort is younger as compared with western cohorts (Table 6). It is worth noting that except for the CKD Japan Cohort (CKD-JAC), other Asian cohorts are younger than Western cohorts by 5–20 years. This finding is consistent with previous descriptions of CKD in India [21], and could be due to number of factors such as differential exposure to environmental risk factors, maternal malnutrition leading to development of kidney disease earlier in life, differences in genetic background or delayed recognition leading to faster disease progression [22]. Data from the nationally representative mortality survey of India in the Million Death Study have shown that the highest burden of age-standardized renal deaths was seen in the 45–69 years age group [2]. Approximately two-thirds of participants in our study cohort are males. A similar observation was noted in a multicentric hospital-based registry of patients with CKD in India [21]. This finding contradicts the global observation of a higher prevalence of milder stage CKD among females [20], and might reflect a systematic barrier in presentation to healthcare facilities for females in India, likely due to socio-cultural reasons.

The average BMI in our cohort was lower than that reported in the western cohorts [5, 19]. We report a higher

---

Table 4. Comparison of socio-demographic and clinical factors between rural and urban subgroups within the study cohort (n = 4056)

| Characteristic                          | Rural (n = 2626) | Urban (n = 1350) | P-value |
|----------------------------------------|------------------|------------------|---------|
| Age, years                             | 50.5 ± 11.6      | 49.8 ± 12.1      | 0.096   |
| BMI, kg/m²                             | 23.8 (21.0–26.8) | 25.3 (23.0–28.4) | <0.001  |
| Waist/hip ratio                        | 1.05 (1.02–1.10) | 1.04 (1.00–1.08) | <0.001  |
| Education                              |                  |                  |         |
| Illiterate                             | 872 (33.21)      | 197 (14.6)       | <0.001  |
| Some schooling                         | 1262 (48.1)      | 624 (46.2)       |         |
| Graduate or above                      | 492 (18.7)       | 529 (39.2)       |         |
| Occupational exposure*                 | 1434 (54.6)      | 560 (41.5)       | <0.001  |
| Sand/dust                              | 644 (24.5)       | 195 (14.4)       | 0.000   |
| Cement                                 | 64 (2.4)         | 22 (1.6)         | 0.097   |
| Saw dust                               | 123 (4.7)        | 22 (1.6)         | 0.000   |
| Working barefoot in field              | 238 (9.1)        | 21 (1.6)         | 0.000   |
| Pesticide spray                        | 213 (8.1)        | 12 (0.9)         | 0.000   |
| Others                                 | 586 (20.9)       | 330 (58.9)       |         |
| Current tobacco user                   | 536 (20.6)       | 203 (15.1)       | <0.001  |
| Current alcohol users                  | 193 (7.4)        | 104 (7.8)        | 0.691   |
| Physically active                      | 1047 (40.2)      | 656 (48.9)       | <0.001  |
| Non-vegetarian diet                    | 1765 (68.2)      | 805 (59.9)       | <0.001  |
| Access to piped water supply           | 1229 (46.8)      | 710 (52.6)       | <0.001  |
| Annual household income (USD)          | 1680 (840–3360)  | 3024 (1512–6720) | <0.001  |
| Annual household medical expenditure (USD) | 268.8 (84–521) | 336 (84–672) | <0.001  |
| Has medical insurance                  | 721 (27.8)       | 531 (39.8)       | <0.001  |
| Out-of-pocket medical expenses         | 2254 (85.8)      | 1049 (77.7)      | <0.001  |
| Clinical characteristic                |                  |                  |         |
| Hypertension                           | 2207 (85.2)      | 1226 (91.2)      | <0.001  |
| Diabetes                               | 933 (36.3)       | 530 (40.0)       | 0.026   |
| CVD                                    | 592 (22.7)       | 257 (19.2)       | 0.010   |
| Renal stone disease                    | 283 (10.8)       | 183 (13.6)       | 0.010   |
| Recurrent UTI                          | 293 (11.2)       | 144 (10.7)       | 0.647   |
| Alternative drug use                   | 561 (21.4)       | 357 (26.4)       | <0.001  |
| Ayurvedic                              | 222 (39.6)       | 141 (39.5)       |         |
| Homoeopathic                           | 135 (24.1)       | 72 (20.2)        |         |
| Siddha                                 | 27 (4.8)         | 24 (6.7)         |         |
| Unani                                  | 10 (1.8)         | 3 (0.8)          |         |
| Others                                 | 167 (29.8)       | 117 (32.8)       |         |
| NSAID use                              | 395 (15.2)       | 217 (16.2)       | 0.397   |
| History of AKI                         | 167 (6.4)        | 98 (7.3)         | 0.283   |
| Required dialysis for AKI              | 158 (6.1)        | 70 (5.2)         | 0.284   |
| Underwent kidney biopsy                | 417 (16.0)       | 264 (19.7)       | 0.004   |

Data are presented as mean ± SD, median (25–75th percentile) or n (%).

*Occupational exposure—has multiple responses.
Table 5. Physical, biochemical characteristics and diagnosis between rural and urban subgroups within the study cohort (n = 4056)

| Characteristic          | Rural (n = 2626) | Urban (n = 1350) | P-value |
|-------------------------|------------------|------------------|---------|
| SBP, mmHg               | 130 (120–143)    | 130 (120–145)    | 0.092   |
| DBP, mmHg               | 80 (78–90)       | 80 (78–90)       | 0.981   |
| eGFR, mL/min/1.73 m²    | 40.0 (33.6–49.7) | 42.0 (34.4–52.7) | <0.001  |
| Hb, g/dL                | 11.6 (10.4–13.0) | 12.1 (10.8–13.5) | <0.001  |
| Anaemia                 | 1712 (67.8)      | 771 (58.8)       | <0.001  |
| Mild                    | 858 (34.0)       | 422 (32.2)       |        |
| Moderate                | 814 (32.2)       | 332 (25.3)       |        |
| Severe                  | 40 (1.6)         | 17 (1.3)         |        |
| Serum urea, mg/dL       | 46.0 (35.3–56.0) | 43.0 (33.1–53.8) | <0.001  |
| Serum creatinine, mg/dL | 1.8 (1.5–2.0)    | 1.7 (1.4–2.0)    | <0.001  |
| Serum calcium, mg/dL    | 9.0 (8.5–9.4)    | 9.0 (8.5–9.5)    | 0.982   |
| Serum inorganic phosphorus, mg/dL | 4.0 (3.3–4.5) | 4.0 (3.3–4.5) | 0.978 |
| Serum albumin, g/dL     | 4.0 (3.5–4.4)    | 4.0 (3.5–4.4)    | 0.203   |
| Serum uric acid, mg/dL  | 6.5 (5.3–7.6)    | 6.2 (5.1–7.5)    | 0.024   |
| Total cholesterol, mg/dL| 171 (137–202)    | 156 (128–194)    | <0.001  |
| Triglycerides, mg/dL    | 138 (110–176)    | 137 (107–178)    | 0.717   |
| HbA1c, %                | 5.7 (5.1–6.9)    | 5.6 (5.0–6.6)    | 0.092   |
| HbsAg-positive status   | 190 (7.3)        | 53 (3.9)         | <0.001  |
| Anti HCV-positive status| 195 (7.4)        | 57 (4.2)         | <0.001  |
| uACR, mg/g              | 25.5 (10.7–304.3)| 41.0 (11.7–304.3)| 0.003   |
| <30                     | 1255 (69.0)      | 613 (64.9)       | –       |
| 30–299                  | 563 (30.97)      | 332 (35.1)       | –       |
| 300–1000                | 364 (15.0)       | 206 (16.2)       | –       |
| >1000                   | 251 (10.3)       | 123 (9.6)        | –       |
| Cause of CKD            |                 |                  | <0.001  |
| DKD                     | 620 (23.6)       | 370 (27.4)       | –       |
| CIN                     | 630 (24.0)       | 283 (21.0)       | –       |
| Unknown                 | 570 (21.7)       | 209 (15.5)       | –       |
| CGN                     | 362 (13.8)       | 220 (16.3)       | –       |
| Hypertensive nephrosclerosis | 196 (7.5) | 123 (9.1)       | –       |
| PKD                     | 92 (3.5)         | 45 (3.3)         | –       |
| Others                  | 156 (5.9)        | 100 (7.4)        | –       |

Data presented as mean ± SD, n (%) and median (25–75th percentile).
SBP, systolic BP; DBP, diastolic BP; HbA1c, glycosylated Hb; HbsAg, hepatitis B surface antigen; HCV, hepatitis C virus.

Table 6. Salient characteristics of major CKD cohort studies in adult population

| Characteristic          | ICKD (n = 4056) | CRIC [5, 18] (n = 3612) | CKD-JAC [6] (n = 2977) | GC KD [19] (n = 5217) | CanPREDICT [7] (n = 2402) | C-STRIDE [11] (n = 3168) | KNOW-CKD [10] (n = 2238) | NEFRONA [8] (n = 2238) |
|-------------------------|-----------------|--------------------------|------------------------|-----------------------|--------------------------|--------------------------|--------------------------|------------------------|
| Age (years), mean ± SD  | 50.3 ± 11.8     | 58.2 ± 11.0              | 60.8 ± 11.6            | 60.1 ± 12.0           | 68.1 ± 12.7              | 48.2 ± 13.7              | 53.7 ± 12.2              | 57.9 ± 12.8            |
| Female sex, %           | 32.8            | 46.0                     | 38.0                   | 40.0                  | 37.0                     | 41.0                     | 38.8                     | 42.3                   |
| BMI, kg/m², mean ± SD   | 24.4 ± 5.8      | 23.1 ± 7.9               | 23.5 ± 3.8             | 29.8 ± 6.0            | 24.5 ± 3.6               | 24.6 ± 3.4               | 28.3 ± 5.2               | –                      |
| eGFR, mL/min/1.73 m²,  | 40.6 ± 17.2     | 43.4 ± 13.5              | 28.6 ± 11.8            | 47.0 ± 17.0           | 28.0 ± 9.0               | 50.7 ± 30.0              | 53.1 ± 30.7              | CKD Stage 3–5D         |
| Diabetes, %             | 37.5            | 47.0                     | 37.6                   | 35.3                  | 48.0                     | 22.8                     | 33.7                     | 25.7                   |
| Hypertension, %         | 87.0            | 86.0                     | 81.5                   | 95.0                  | Not available            | 77.8                     | 96.1                     | 89.3                   |
| CVD, %                  | 21.8            | 33.0                     | 25.6                   | 32.2                  | 22.0                     | 9.8                      | 6.0                      | NA                     |
| Tobacco use, %          | 18.6            | 14.0                     | 16.4                   | 14.9                  | Not available            | 38.2                     | 15.7                     | 19.4                   |
| Major cause of CKD      | DKD (24.9)      | DKD (25.5)                | DKD (20.6)             | DKD (15.0)            | DKD (29.0)               | DKD (13.9)               | DKD (22.2)               | DKD (14.4)             |
|                         | CGN (14.7)      | HTN (14.5)                | CGN (31.9)             | CGN (19.0)            | CGN (11.0)               | CGN (60.6)               | CGN (15.6)               | CGN (15.6)             |
|                         | HTN (7.9)       | Other (13.7)              | Others (47.5)          | Vascular nephropathy  | PKD (4.0)                | Others (25.6)            | PKD (18.3)               | Vascular nephropathy    |
|                         | Cin (23.2)      | Do not know (46.3)        | Unknown (19.4)         | Interstitial nephropathy (23.0) | Others (29.0)             | Unknown (6.1)            | Unknown (16.1)           | tubulointerstitial (11.7) |
|                         | Unknown (20)    |                           |                        |                      |                          |                          |                          |                       |
proportion of tobacco users, a potentially modifiable CKD risk factor [23] than that in the Chronic Renal Insufficiency Cohort (CRIC), CKD-JAC and German CKD (GCKD) cohorts [5, 6, 19]. Consumption of tobacco, especially in smokeless forms, is a deeply ingrained cultural practice in many parts of India [24]. The Chinese Cohort Study of CKD (C-STRIDE) has reported an even higher prevalence of tobacco use, at 38.2% [11].

Sedentary life style is another modifiable risk factor for CVD and CKD [25]. Just 43% of participants in our cohort reported physical activity corresponding to brisk walk for 30 min on at least 5 days in a week. In the Korean Cross-Sectional Study for Outcomes in Patients With CKD (KNOW-CKD) study, physical activity equivalent to that in our cohort was reported by 38.4% of participants [26], and 50% of C-STRIDE participants exercised >3.5 h/week [11]. Taken together, these data show that sedentary habits are common in patients with CKD. As exercise can favourably modulate renal function and control of hypertension in patients with CKD [27], it represents an important intervention that has potential to improve outcomes.

A total of 23% of our cohort participants had used alternative drugs, both before and after the diagnosis of CKD. India has several traditional medical systems that use herbal remedies, but the contribution of these medicines in the development and/or progression of CKD in India is not known. Most of the published data come from China and Taiwan, where higher rates of CKD are documented among consumers of indigenous Chinese herbal medicines [28, 29]. However, recent data from large insurance databases suggest that the associations may be complex and need well-structured exploration [30–33].

Diabetes was the most common cause of CKD (25%). An important finding was the emergence of CIN as the second most common, followed by CKDu. The 2012 Indian CKD Registry report showed DKD to be the designated aetiology in 31%, followed by CKDu at ~19% and CGN at 14% [21]. CIN and CKDu have an almost identical phenotype and there are no clear criteria that allow distinction between the two. Usually, patients with no apparent risk factors are assigned a diagnosis of ‘unknown’. In the setting of long-standing hypertension (>5 years) without other risk factors, a diagnosis of hypertensive nephrosclerosis was assigned. The aetiologic distribution in our cohort is consistent with the recent population-based reports on CKD in India [34–37]. Elucidating the cause in these cases with unknown cause is an important research agenda. The possibility to do additional studies using platform technologies on the biobanked samples holds promise to improve our understanding of potential causes and risk factors.

Only about one-third of the patients enrolled in the study had any medical insurance. Furthermore, >80% of the participants ended up paying the majority of their healthcare costs from their own pocket, which suggests that even when insurance is available, it does not cover all aspects of CKD care.

Almost two-thirds of the ICKD participants were rural, which reflects the population distribution in India. There were some differences between participants from urban and rural areas. Rural participants were less educated, had lower earnings with lower insurance coverage, were more likely to be engaged in manual work and had more hazardous occupational exposure. Tobacco use was also higher among rural participants, while self-reported physical activity was lower in the rural group. Consistent with previous reports, CKDu was identified more frequently in the rural participants. Such findings are being increasingly described from other studies in rural populations in India [38]. Taken together, these data reinforce differences in epidemiology of CKD between urban and rural regions and suggest dominant tubulo-interstitial injury on account of as yet unknown risk factors in rural communities. Elucidation of differences in the characteristics and risk factor profile set the stage for further exploration of causality and development of customized strategies for management and prevention of CKD in rural regions.

Table 6 shows the comparison between selected features of the ICKD cohort and CRIC, GCKD, CKD-JAC, the Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT), C-STRIDE, KNOW-CKD and Observatorio Nacional de Aterosclerosis en Nefrologia (NEFRONA). The frequency of CVD was somewhat lower compared with the western cohorts, but greater than in the Asian cohorts. Proportionally higher representation of males, CIN as one of the dominant causes and lack of clinically apparent cause for CKD in one-fifth of participants are other differences in comparison with other cohorts.

While the ICKD cohort offers a unique opportunity to explore the natural history and progression factors for CKD in Indian subjects, a few limitations should be acknowledged. Except for two, all participating centres in our study are public sector hospitals. Therefore, there may be proportionally more representation of patients belonging to lower socio-economic status. Also, our cohort is hospital-based and may not be reflective of CKD in patients who do not present to nephrologists. The latter population might disproportionately include disadvantaged people living in both urban and rural areas. In addition to population differences, variability in practice patterns and access to healthcare services may be responsible for some of the observed differences.

These limitations notwithstanding, the ICKD study is the only large cohort study of patients with mild-to-moderate CKD in a lower middle income country. Its strengths are the pan-India nature, detailed phenotyping, biobanking and rigorous follow-up. The baseline characteristics show unique features that differentiate this population from patients with CKD enrolled in other cohort studies. Given the high and growing disease burden, a relatively rapid rate of progression, the high cost of care and the impact on quality of life [39], data from this study will provide important information to help the national strategy to manage CKD in India. In addition to defining outcomes and finding factors that associate with adverse outcomes in patients with CKD in low-resource settings, the ICKD study offers opportunities for international comparisons to further the goals of the global nephrology community.

SUPPLEMENTARY DATA

Supplementary data are available at ckj online.

FUNDING

This study was funded by Department of Biotechnology, Ministry of Science and Technology grant (Grant No. BT/PR11105/MED/30/1345/2014).

CONFLICT OF INTEREST STATEMENT

V.J. has research grants from Baxter, GlaxoSmithKline and reports consultancy and advisory board honoraria from Baxter Healthcare and AstraZeneca, outside the published work. All other authors reported no conflict of interest.
**DATA AVAILABILITY STATEMENT**

The study data is not publicly available but can be made available on request.

**REFERENCES**

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395: 709–733
2. Dare AJ, Fu SH, Patra J et al.; Million Death Study Collaborators. Renal failure deaths and their risk factors in India 2001–13: nationally representative estimates from the Million Death Study. Lancet Glob Health 2017; 5: e89–e95
3. Parameswaran S, Geda SB, Rathi M et al. Referral pattern of patients with end-stage renal disease at a public sector hospital and its impact on outcome. Natl Med J India 2011; 24: 208–213
4. Jha V, Ur-Rashid H, Agarwal SK et al.; ISN South Asia Regional Board. The state of nephrology in South Asia. Kidney Int 2019; 95: 31–37
5. Lash JP, Go AS, Appel LJ et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4: 1302–1311
6. Imai E, Matsuo S, Makino H et al. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol 2010; 14: 558–570
7. Levin A, Rigatto C, Brendan B et al.; International Network of Chronic Kidney Disease Cohort Studies (iNET-CKD) cohorts. A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. Kidney Int 2019; 96: 1217–1233
8. Kumar V, Yadav AK, Gang S et al. Indian chronic kidney disease: design and methods. Nephrol (Carlton) 2017; 22: 273–278
9. Sumida K, Nadkarni GN, Grams ME et al.; Chronic Kidney Disease Prognosis Consortium. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann Intern Med 2020; 173: 426–435
10. Censustrack India. 2011. http://www.databuff.or/dashboard/censustrack/ (20 August 2021, date last accessed)
11. CRIC Data View. https://shiny.pmacs.upenn.edu/CRIC_DataView/ (20 August 2021, date last accessed)
12. Titze S, Schmid M, Kottgen A et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 2015; 30: 441–451
13. Neugarten J, Golestanine J. Influence of sex on the progression of chronic kidney disease. Mayo Clin Proc 2019; 94: 1339–1356
14. Rajapakur MM, John GT, Kirpalani AL et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol 2012; 13: 10
15. Islam SM, Purnat TD, Phuong NT et al. Non-communicable diseases (NCDs) in developing countries: a symposium report. Global Health 2014; 10: 81
16. Orth SR, Ogata H, Ritz E. Smoking and the kidney. Nephrol Dial Transplant 2000; 15: 1509–1511
17. V. Kumar. Acute kidney injury revascularization. Ann Intern Med 2000; 15: 1509–1511
18. Caforio ALP, Ardissino D, Atar D et al.; ESC Scientific Document Group. ESC guidelines for the diagnosis and management of acute and chronic heart failure 2016: the Task Force for the diagnosis and management of acute and chronic heart failure 2016 of the European Society of Cardiology. Eur Heart J 2016: 37: 2577–2625
19. LaGrange P, Wear ML, Matsumoto S et al. Drug exposure and adherence in chronic kidney disease: a systematic review. Am J Kidney Dis 2019; 73: 412–424
20. Hyun YY, Lee KB, Han SH et al. Nutritional status in adults with predialysis chronic kidney disease: KNOW-CKD study. J Korean Med Sci 2017; 32: 257–263
21. Wu X, Yang L, Wang Y et al. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis. Clin Rehabil 2020; 34: 851–865
22. Haieh CF, Huang SL, Chen CL et al. Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Prev Med 2012; 55: 155–159
23. Lai MN, Lai JN, Chen PC et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis 2010; 55: 507–518
24. Chen HY, Pan HC, Chen YC et al. Traditional Chinese medicine use is associated with lower end-stage renal disease and mortality rates among patients with diabetic nephropathy: a population-based cohort study. BMC Complement Altern Med 2019; 19: 81
25. Guo JC, Pan HC, Yeh BY et al. Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients: a retrospective population-based cohort study. Front Pharmacol 2021; 12: 616522
26. Heung M, Steffick DE, Zivin K et al. Acute kidney injury recovery pattern and subsequent risk of CKD: an analysis of
veterans health administration data. Am J Kidney Dis 2016; 67: 742–752

33. Lin MY, Chiu YW, Chang JS et al. Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease. Kidney Int 2015; 88: 1365–1373

34. Tatapudi RR, Rentala S, Gullipalli P et al. High prevalence of CKD of unknown etiology in Uddanam, India. Kidney Int Rep 2019; 4: 380–389

35. Rajapakse S, Shivanthan MC, Selvarajah M. Chronic kidney disease of unknown etiology in Sri Lanka. Int J Occup Environ Health 2016; 22: 259–264

36. Weiner DE, McClean MD, Kaufman JS et al. The Central American epidemic of CKD. Clin J Am Soc Nephrol 2013; 8: 504–511

37. O’Callaghan-Gordo C, Shivashankar R, Anand S et al. Prevalence of and risk factors for chronic kidney disease of unknown etiology in India: secondary data analysis of three population-based cross-sectional studies. BMJ Open 2019; 9: e023353

38. Anupama YJ, Uma G. Prevalence of chronic kidney disease among adults in a rural community in South India: results from the kidney disease screening (KIDS) project. Indian J Nephrol 2014; 24: 214–221

39. Modi GK, Yadav AK, Ghosh A et al. Nonmedical factors and health-related quality of life in CKD in India. Clin J Am Soc Nephrol 2020; 15: 191–199